secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0000105770-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback
--------------------------------------------------------------------------------

- Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.
- Full-year 2022 net sales $2.887B (+2.0% reported, +7.7% organic); reported EPS $7.73, adjusted EPS $8.58.
- FY 2023 guidance: net sales $2.935-2.960B, adj. EPS $7.25-7.40; COVID sales ~$85M (vs $388M in 2022).
- Board approved new $1.0B share repurchase program, no expiration; prior program expired Dec 31, 2022.
- Operating cash flow $724.0M (+24%); free cash flow $439.4M (+32.9%); capex $284.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/wst-20230215.htm
  HTML page:      https://secwatch.observer/filing/0000105770-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer